Clinical Trial Update: Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A phase 2 trial is evaluating the combination of atezolizumab and cobimetinib in patients with metastatic, recurrent, or refractory non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING